EconDefense
ACQ-52 / Acquisition, transition and contract finance

Indemnify unusually hazardous research/development work

Military-department R&D contracts may promise U.S. indemnification for defined unusually hazardous direct-performance third-party claims and contractor-property loss not otherwise insured/compensated.

Authority / instrument · ACQ-52

Contract relief & risk allocation

Acquisition, transition and contract finance

Statute & instrument
Authority holder

Secretary of the military department concerned approves; Secretary/designated official certifies payment

What this does not authorize / hard limit

Not blanket indemnity for any contractor business loss or retroactive unstated promise.

Recorded executor

Contracting officer and claims/insurance officials

Continue to actor →

Recorded executing role; this record-specific route is not an additional institutional office.

Legal basisSources linkedLegal sources and instrument limits are recorded.
RequirementsGates recordedRead the requirements for this instrument; applicability depends on the proposed action.
Public fundingRules recordedPayments may use obligated contract funds, unobligated R&D funds or appropriations for payments, with Secretary approval. Office budget figures are separate institutional context, not an allocation to this instrument.
Assigned rolesRoles recordedPublic sources describe institutional authority. The instrument identifies approval and execution roles; a specific signature remains transaction-dependent.
EngagementProcess sourcedThe current R&D deviation supplies explicit section 3861 contract clauses and risk-definition approvals. This is a negotiated contractual protection, not generic business insurance. Program check: 2026-10-04; see each route for intake status.

Public evidence describes the institution and instrument; it is not approval of an individual transaction.

At a glance

Possible toolACQ-52 · Other statutory tools
Legal basis10 U.S.C. §3861

Authority holder: Secretary of the military department concerned approves; Secretary/designated official certifies payment

Other statutory tools

Mechanism tags describe the source text; they do not expand the authority.

Availability and verification

Express statutory pathway; award-specific appropriations, available balances, delegations, implementation and approvals not independently verified.

Program process and intake

Checked 2026-10-04 · process documented. Program evidence is separate from legal authority, available funds and transaction approval.

The current R&D deviation supplies explicit section 3861 contract clauses and risk-definition approvals. This is a negotiated contractual protection, not generic business insurance.

Unusually hazardous R&D contract indemnification

Who this route serves
Contractors performing qualifying R&D work
Administering office / routing lead
Contracting officer and Secretary-level/designated approving authority under applicable delegation
Direct implementation

DFARS 235.174 and clauses 252.235-7000/7001 expressly implement 10 U.S.C. 3861.

What this evidence label means
Current clauses documented

February 2026 Part 35 deviation relocates the process to 235.174/235.176; older 235.070 citations may be stale.

Status reference date: 2026-10-04 · research checked 2026-10-04

DoD RFO Part 35 deviation 2026-O0014 · 235.174; 235.176; 252.235-7000 and -7001official acquisition deviation · Evidence record

Program eligibility

  • Risk must arise from direct contract performance, be unusually hazardous as defined in the contract, and meet the uninsured-loss conditions.

    DoD RFO Part 35 deviation 2026-O0014 · 235.174; 235.176; 252.235-7000 and -7001official acquisition deviation · Evidence record

Steps and preparation

  • Obtain approval of the specific hazard definition and insert the prescribed fixed-price or cost-reimbursement clause; maintain available required/approved insurance and follow claim-notice/defense obligations.

    DoD RFO Part 35 deviation 2026-O0014 · 235.174; 235.176; 252.235-7000 and -7001official acquisition deviation · Evidence record
Funding, limits and authority relationship

Funding and financial terms

  • contract contingent-risk allocation · contract-specific

    Protection is contingent indemnification, not an up-front project award; clause conditions exclude covered losses already compensated by insurance.

    DoD RFO Part 35 deviation 2026-O0014 · 235.174; 235.176; 252.235-7000 and -7001official acquisition deviation · Evidence record

Exclusions and limits

  • No lost-profit or managerial misconduct protection is promised; mixed R&D/other work requires separating3861 from the additional85-804 basis.

    DoD RFO Part 35 deviation 2026-O0014 · 235.174; 235.176; 252.235-7000 and -7001official acquisition deviation · Evidence record

Authority relationship source

DoD RFO Part 35 deviation 2026-O0014 · 235.174; 235.176; 252.235-7000 and -7001official acquisition deviation · Evidence record

Read R&D indemnity procedures and clauses →

published guidance: Negotiate through the contract’s warranted contracting officer; no open standalone program.

Research scope and sources checked

Read current Part35 scope and full fixed-price clause, plus Part50 mixed-work rule; kept distinct bases separate and avoided assigning this authority to an ordinary insurance or nuclear-program announcement.

What remains unverified

  • No specific approved risk definition, contractor indemnification agreement or paid claim independently verified.

A dated source check is not continuing monitoring. Recheck the linked official notice before preparing a submission. Browse program research →

Requirements and limits

Eligibility & prerequisites

  • Risk defined as unusually hazardous in contract; direct performance connection and uncovered loss.
  • Required notice of claims/suits and U.S. option to control/assist defense.

Limits & exclusions

  • Not blanket indemnity for any contractor business loss or retroactive unstated promise.
  • R&D statutory pathway is distinct from 50 U.S.C. §1431 Presidential emergency relief.

Funding conditions

  • Payments may use obligated contract funds, unobligated R&D funds or appropriations for payments, with Secretary approval.

Read the funding and execution guide

Who contributes what

Need & planning

  • R&D program and contractor

Resources

  • EligibleR&D/contract funds

Approval

  • Military-department Secretary; designated just-and-reasonablepayment certifier

Execution

Partners & review

  • DCMA asappropriate; counsel; risk/insurance specialists

Office links are editorial matches to the original role text, not verified delegations. Composite labels and unmatched actors are preserved.

Coordination pathway

R&D program identifies hazard → insurance/risk counsel review → Secretary approval → explicit contract clause → certified claim payment.

Actor and execution-role sources

What this research establishes

Legal basisSources linkedLegal sources and instrument limits are recorded.
RequirementsGates recordedRead the requirements for this instrument; applicability depends on the proposed action.
Public fundingRules recordedPayments may use obligated contract funds, unobligated R&D funds or appropriations for payments, with Secretary approval. Office budget figures are separate institutional context, not an allocation to this instrument.
Assigned rolesRoles recordedPublic sources describe institutional authority. The instrument identifies approval and execution roles; a specific signature remains transaction-dependent.
EngagementProcess sourcedThe current R&D deviation supplies explicit section 3861 contract clauses and risk-definition approvals. This is a negotiated contractual protection, not generic business insurance. Program check: 2026-10-04; see each route for intake status.

Confidence: High on express authority and cited conditions; execution assignment is illustrative unless statute expressly names it.

Currentness: GovInfo 2024 Code (includes FY2025 NDAA, P.L. 118-159) read in full for cited provision; targeted FY2026 NDAA P.L. 119-60 amendment/repeal sweep. No claim of complete legislative currency through 2026-10-02; remaining 2026 delta needs counsel validation.

Review scope: Original research target October 2, 2026; no record-specific last-review date supplied. Publication is not legal-currentness certification.